|
You are subscribed to Oncology (Cancer) / Hematologic Malignancies. This information has recently been updated, and is now available.
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
|
This email was sent to Esdek@podam.pl using Granicus Communications Cloud on behalf of: U.S. Food and Drug Administration ·
10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA |
 |
|
|
